ARKG VS FBT: Tracking Methods and Exposure
Exchange-Traded Funds (ETFs) have transformed the investment landscape, providing investors with diversified exposure to a wide range of sectors and asset classes. In this article, we will conduct an in-depth comparison between two prominent ETFs: ARKG (ARK Genomic Revolution ETF) and FBT (First Trust NYSE Arca Biotechnology Index Fund). Throughout this analysis, we'll explore various facets including ETF tickers, full names, issuers, sectors, top holdings, capitalization, investment strategy, tracking methods, and exposure characteristics.
ARKG VS FBT: Overview
ARKG and FBT are distinct ETFs that focus on the biotechnology sector. However, they differ in their investment strategies and underlying holdings. ARKG, managed by ARK Invest, aims to capture opportunities within the genomics revolution, investing in companies at the forefront of advancements in genetics, molecular biology, and biotechnology. FBT, on the other hand, seeks to track the NYSE Arca Biotechnology Index, which includes a diverse array of biotech companies. This contrast in investment approach leads to differing risk profiles and potential returns, which we'll delve into further.
ARKG VS FBT: Sectors and Top Holdings
ARKG concentrates its portfolio on innovative companies involved in genomics, gene editing, and related fields. Some of its top holdings include companies like Teladoc Health, CRISPR Therapeutics, and Pacific Biosciences of California. FBT's holdings encompass a broader range of biotechnology companies, which can provide exposure to various stages of drug development, clinical trials, and commercialization. Understanding the sectors and top holdings helps investors assess the potential growth and volatility of each ETF.
ARKG overlap ARKG VS FBT: A Comprehensive Comparison of ETFs
ARKG VS FBT: Capitalization and Investment Strategy
ARKG boasts substantial assets under management (AUM) due to its thematic approach that resonates with investors seeking exposure to cutting-edge biotech advancements. ARK Invest's strategy involves identifying disruptive technologies and investing in companies positioned to benefit from them. FBT, managed by First Trust Advisors, provides a diversified basket of biotech stocks, aiming to mirror the performance of the NYSE Arca Biotechnology Index. The difference in capitalization and investment strategy underscores the distinct approaches that these ETFs take to achieve their objectives.
ARKG VS FBT: Tracking Methods and Exposure
ARKG's objective is to capture the growth potential of genomics and related technologies by investing in companies with innovative solutions. Its portfolio managers actively research and analyze companies' potential, often taking a long-term view. FBT, as an index-tracking ETF, mirrors the performance of the NYSE Arca Biotechnology Index, which includes established biotech firms. Understanding the tracking methods and exposure characteristics is crucial for investors seeking to align their investments with their risk tolerance and market outlook.
Conclusion
ARKG and FBT present investors with distinct avenues to gain exposure to the biotechnology sector. For those seeking deeper insights into holdings, correlations, overlaps, and other relevant information, ETF Insider serves as an invaluable tool. Through its user-friendly app, it offers comprehensive details about these and other financial instruments, enabling investors to make informed decisions tailored to their investment goals.
Disclaimer: This article does not provide any investment advisory services.
Sources:
ARK Invest. (n.d.). ARK Genomic Revolution ETF (ARKG). Retrieved [Date], from [URL]
First Trust. (n.d.). First Trust NYSE Arca Biotechnology Index Fund (FBT). Retrieved [Date], from [URL]
ARKG ETF issuer
ARKG ETF official page
FBT quote and analysis
Discover the top holdings, correlations, and overlaps of ETFs using our visualization tool.
Our app allows you to build and track your portfolio.
To learn more about the FBT First Trust NYSE Arca Biotechnology Index Fund, access our dedicated page now.